Subscribe to Updates

    Get the latest creative news from CRYPTO NOUNCE.

    What's Hot

    ApeCoin community declines creation of multi-link APE NFTs, here’s why

    March 27, 2023

    Australia’s prudential regulator says banks well equipped to handle a crisis By Reuters

    March 27, 2023

    Binance CEO CZ rejects allegations of market manipulation

    March 27, 2023
    Facebook Twitter Instagram
    Facebook Twitter Instagram Vimeo
    Cryptonounce.com
    Contact
    • Business
      • Deals
      • investors
      • IPO
      • Startups
      • Wall Street
    • Markets
      • Bonds
      • Commodities & Futures
      • Currencies
      • Funds & ETFs
      • Stocks
    • Crypto
      • Alticoins News
      • Binance News
      • Bitcoins News
      • Blockchain News
      • Ethereum News
      • Token Sales News
      • XRP News
    • Technology
      • Artificial Intelligence
      • Big Data
      • Cloud Computing
      • Cybersecurity
      • Gaming
      • Internet of Things
      • Mobile
      • Social Media
      • Transportation
      • VR & AR
    • FinTech
    • Personal finance
    • Grides
      • Crypto
      • FinTech
      • Investing
      • Personal Finance Guides
      • Techonology
    • Tools
      • Coins
      • ICO List
      • Organigations
      • Events
    Cryptonounce.com
    Home » CytomX shares surge more than 50% on Moderna partnership
    Markets

    CytomX shares surge more than 50% on Moderna partnership

    AdmincryptBy AdmincryptJanuary 5, 2023No Comments1 Min Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email
    Share
    Facebook Twitter LinkedIn Pinterest Email


    CytomX Therapeutics Inc.
    CTMX,
    +40.78%

    shares soared more than 50% in the extended session Thursday after the small biotech company announced a partnership with Moderna Inc.
    MRNA,
    +3.94%

    CytomX shares were last up 57% after hours, following a 7.2% rise to close the regular session at $1.79. Under the agreement, CytomX gets a $35 million up-front payment, and is eligible for up to $1.2 billion in additional payments to research and develop “messenger RNA-based conditionally activated therapeutics” with Moderna. The company also reported “encouraging clinical activity” in its CX-2029 clinical trials in partnership with AbbVie Inc.
    ABBV,
    +1.87%

     



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Previous ArticleWalgreens Boots Alliance (WBA) Q1 earnings 2023
    Next Article China’s NFT market, Moutai metaverse popular but buggy… – Cointelegraph Magazine
    Admincrypt
    • Website

    Related Posts

    Australia’s prudential regulator says banks well equipped to handle a crisis By Reuters

    March 27, 2023

    Australia would not allow AT1 debt security holder wipe-out -minister By Reuters

    March 27, 2023

    Lyft taps former Amazon exec Risher as new CEO after founders step down By Reuters

    March 27, 2023

    Pinterest sheds S.F. office space

    March 27, 2023

    Leave A Reply Cancel Reply

    Our Picks
    • Facebook
    • Twitter
    • Pinterest
    • Instagram
    • YouTube
    • Vimeo
    Don't Miss
    XRP News

    ApeCoin community declines creation of multi-link APE NFTs, here’s why

    By AdmincryptMarch 27, 20230

    The ApeCoin DAO is in the process of rejecting the AIP-206 proposal. Most of Yuga…

    Australia’s prudential regulator says banks well equipped to handle a crisis By Reuters

    March 27, 2023

    Binance CEO CZ rejects allegations of market manipulation

    March 27, 2023

    The first quarter of 2023 is about to end. ‘Fast Money’ traders look ahead to earnings season

    March 27, 2023

    Subscribe to Updates

    Get the latest creative news from CRYPTO NOUNCE.

    NEWS
    • Business
    • Crypto
    • Blockchain
    • Markets
    • Technology
    FEATURED SECTIONS
    • Coins
    • ICO List
    • Organigations
    • Events
    • Grides
    FEATURED LINKS
    • Story of the day
    • Videos
    • Infographics
    CONNECT WITH US
    • Facebook
    • Twitter
    • Telegram
    • LinkedIn
    • Pinterest
    ABOUT US
    • Contact
    • Advertise
    • Sitemap
    Copyright © 2023 Cryptonounce All rights reserved. Cryptonounce.
    • Home
    • Buy Now

    Type above and press Enter to search. Press Esc to cancel.

    Sign In or Register

    Welcome Back!

    Login to your account below.

    Lost password?